{
    "pmcid": "8491763",
    "qa_pairs": {
        "How do nanobodies potentially maintain efficacy against emerging variants of SARS-CoV-2?": [
            "By targeting conserved regions of the S protein.",
            "By rapidly mutating to match new viral strains.",
            "By binding to the viral RNA instead of proteins.",
            "By enhancing the host's immune response to the virus."
        ],
        "What advantage do nanobodies have over conventional antibodies according to the paper?": [
            "They can access cryptic epitopes on the S protein.",
            "They have a longer half-life in the bloodstream.",
            "They are less expensive to produce in mammalian cells.",
            "They require less engineering to achieve high specificity."
        ],
        "What is one potential application of nanobodies in the fight against COVID-19 mentioned in the paper?": [
            "Complementing existing therapeutic strategies like monoclonal antibodies and vaccines.",
            "Replacing all current vaccines due to their superior efficacy.",
            "Acting as a standalone treatment for all COVID-19 cases.",
            "Being used exclusively in diagnostic tests for SARS-CoV-2."
        ],
        "What is the primary focus of the paper titled 'Mechanisms of SARS-CoV-2 entry into cells'?": [
            "The interaction of the spike protein with the ACE2 receptor.",
            "The role of the immune system in fighting SARS-CoV-2.",
            "The development of vaccines against SARS-CoV-2.",
            "The genetic mutations of SARS-CoV-2."
        ],
        "Which proteases are mentioned as facilitating the entry of SARS-CoV-2 into host cells?": [
            "Furin, TMPRSS2, and cathepsin L.",
            "Trypsin, pepsin, and elastase.",
            "Papain, bromelain, and collagenase.",
            "Serine protease, metalloprotease, and cysteine protease."
        ]
    }
}